Announcements Trials
Browse Landscape

Phase

Phase 4 2

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Stomach Neoplasms 1Gastroesophageal Reflux 1

Interventions

Oxaliplatin 21Capecitabine 19Fluorouracil 16Bevacizumab 16Esomeprazole 11Sorafenib 10Irinotecan 9Leucovorin 8Radiofrequency Ablation 7Propofol 7Bismuth 7Morphine 6Gemcitabine 6Folfox protocol 6Amoxicillin 6lenvatinib 5gadolinium ethoxybenzyl DTPA 5Tetracycline 5Sevoflurane 5S 1 (combination) 5Drug Therapy 5Control Groups 5Cisplatin 5sodium glycididazole 4fish oil triglycerides 4ferric carboxymaltose 4Sodium Chloride 4Ropivacaine 4Ribavirin 4Hepatectomy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × ilaprazole × Gastrointestinal × Clear all
NCT02638584 2020-07-31

Effects of Ilaprazole on Ulcer Healing Rate and Prevention of Gastrointestinal Bleeding in the Patients Undergone ESD.

Il-Yang Pharm. Co., Ltd.

Phase 4 Completed
176 enrolled
Gastrointestinal

Stomach Neoplasms

NCT02666976 2019-03-22

The Prospective Study on the Effect of Ilaprazole in Non-erosive Reflux Disease Patients; Focused on Histologic Findings and Inflammatory Biomarker

Yonsei University

Phase 4 Completed
20 enrolled
Gastrointestinal

Gastroesophageal Reflux

Data powered by HemOnc (CC BY 4.0) Colophon âš¡